These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 37991626)

  • 1. Polypill and Combination Therapy: Blood Pressure and Cardiovascular Risk Reduction.
    Park J; Yang CW; Huan Y; Aggarwal S
    Curr Cardiol Rep; 2023 Dec; 25(12):1851-1858. PubMed ID: 37991626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
    Lafeber M; Spiering W; Visseren FL; Grobbee DE; Bots ML; Stanton A; Patel A; Prabhakaran D; Webster R; Thom S; Rodgers A;
    Eur J Prev Cardiol; 2017 Jun; 24(9):951-961. PubMed ID: 28436727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypertension therapy using fixed-dose polypills that contain at least three medications.
    O'Hagan ET; McIntyre D; Nguyen T; Chow CK
    Heart; 2023 Aug; 109(17):1273-1280. PubMed ID: 36810213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effect of a Cardiovascular Polypill Strategy on Pill Burden.
    Truelove M; Patel A; Bompoint S; Brown A; Cass A; Hillis GS; Peiris D; Rafter N; Reid CM; Rodgers A; Tonkin A; Usherwood T; Webster R;
    Cardiovasc Ther; 2015 Dec; 33(6):347-52. PubMed ID: 26280247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The evening versus morning polypill utilization study: the TEMPUS rationale and design.
    Lafeber M; Grobbee DE; Bots ML; Thom S; Webster R; Rodgers A; Visseren FL; Spiering W
    Eur J Prev Cardiol; 2014 Apr; 21(4):425-33. PubMed ID: 23382539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges.
    ; Yusuf S; Attaran A; Bosch J; Joseph P; Lonn E; McCready T; Mente A; Nieuwlaat R; Pais P; Rodgers A; Schwalm JD; Smith R; Teo K; Xavier D
    Eur Heart J; 2014 Feb; 35(6):353-64. PubMed ID: 24288261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular disease.
    Agarwal A; Mehta PM; Jacobson T; Shah NS; Ye J; Zhu J; Wafford QE; Bahiru E; de Cates AN; Ebrahim S; Prabhakaran D; Rodgers A; Huffman MD
    Nat Med; 2024 Apr; 30(4):1199-1209. PubMed ID: 38532223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A polypill strategy to improve adherence: results from the FOCUS project.
    Castellano JM; Sanz G; Peñalvo JL; Bansilal S; Fernández-Ortiz A; Alvarez L; Guzmán L; Linares JC; García F; D'Aniello F; Arnáiz JA; Varea S; Martínez F; Lorenzatti A; Imaz I; Sánchez-Gómez LM; Roncaglioni MC; Baviera M; Smith SC; Taubert K; Pocock S; Brotons C; Farkouh ME; Fuster V
    J Am Coll Cardiol; 2014 Nov 18-25; 64(20):2071-82. PubMed ID: 25193393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fixed-dose combination therapy in hypertension: cons.
    Angeli F; Reboldi G; Mazzotta G; Garofoli M; Ramundo E; Poltronieri C; Verdecchia P
    High Blood Press Cardiovasc Prev; 2012 Jun; 19(2):51-4. PubMed ID: 22867089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial.
    Thom S; Poulter N; Field J; Patel A; Prabhakaran D; Stanton A; Grobbee DE; Bots ML; Reddy KS; Cidambi R; Bompoint S; Billot L; Rodgers A;
    JAMA; 2013 Sep; 310(9):918-29. PubMed ID: 24002278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial.
    Singh K; Crossan C; Laba TL; Roy A; Hayes A; Salam A; Jan S; Lord J; Tandon N; Rodgers A; Patel A; Thom S; Prabhakaran D
    Int J Cardiol; 2018 Jul; 262():71-78. PubMed ID: 29622506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-Pill Triple Fixed Dose Combination Therapy with Single Component Drug Monitoring in Treatment-Resistant Hypertension: A Pilot Study.
    Kreutz R; Scholze J; Douros A
    Curr Vasc Pharmacol; 2018 Jan; 16(2):197-203. PubMed ID: 28828980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease.
    Lafeber M; Webster R; Visseren FLj; Bots ML; Grobbee DE; Spiering W; Rodgers A;
    Eur J Prev Cardiol; 2016 Aug; 23(12):1289-97. PubMed ID: 26743587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multifactorial Prevention of Cardiovascular Disease in Patients with Hypertension: the Cardiovascular Polypill.
    Lafeber M; Spiering W; Visseren FL; Grobbee DE
    Curr Hypertens Rep; 2016 Apr; 18(5):40. PubMed ID: 27083928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The feasibility of polypill for cardiovascular disease prevention in Asian Population.
    Sukonthasarn A; Chia YC; Wang JG; Nailes J; Buranakitjaroen P; Van Minh H; Verma N; Hoshide S; Shin J; Turana Y; Tay JC; Teo BW; Siddique S; Sison J; Zhang YQ; Wang TD; Chen CH; Kario K
    J Clin Hypertens (Greenwich); 2021 Mar; 23(3):545-555. PubMed ID: 33086429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
    Roshandel G; Khoshnia M; Poustchi H; Hemming K; Kamangar F; Gharavi A; Ostovaneh MR; Nateghi A; Majed M; Navabakhsh B; Merat S; Pourshams A; Nalini M; Malekzadeh F; Sadeghi M; Mohammadifard N; Sarrafzadegan N; Naemi-Tabiei M; Fazel A; Brennan P; Etemadi A; Boffetta P; Thomas N; Marshall T; Cheng KK; Malekzadeh R
    Lancet; 2019 Aug; 394(10199):672-683. PubMed ID: 31448738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fixed Low-Dose Triple Combination Antihypertensive Medication vs Usual Care for Blood Pressure Control in Patients With Mild to Moderate Hypertension in Sri Lanka: A Randomized Clinical Trial.
    Webster R; Salam A; de Silva HA; Selak V; Stepien S; Rajapakse S; Amarasekara S; Amarasena N; Billot L; de Silva AP; Fernando M; Guggilla R; Jan S; Jayawardena J; Maulik PK; Mendis S; Mendis S; Munasinghe J; Naik N; Prabhakaran D; Ranasinghe G; Thom S; Tisserra N; Senaratne V; Wijekoon S; Wijeyasingam S; Rodgers A; Patel A;
    JAMA; 2018 Aug; 320(6):566-579. PubMed ID: 30120478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fixed-dose triple-combination treatments in the management of hypertension.
    Ram CV
    Manag Care; 2013 Dec; 22(12):45-55. PubMed ID: 24555265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe.
    Thom S; Field J; Poulter N; Patel A; Prabhakaran D; Stanton A; Grobbee DE; Bots ML; Reddy KS; Cidambi R; Rodgers A
    Eur J Prev Cardiol; 2014 Feb; 21(2):252-61. PubMed ID: 23038750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of a Polypill to Reduce Cardiovascular Events: A Review of Clinical Trials.
    Kelly MS; Dacey A; Siana A; Ojeda J
    J Cardiovasc Pharmacol; 2024 Jan; 83(1):8-15. PubMed ID: 37924288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.